Castle Biosciences News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

15.07.20	Castle Biosciences Announces Publication of Clinical Utility, Long-Term Outcomes Data and Meta-Analysis for DecisionDx-UM for Patients with Uveal Melanoma (Businesswire)
09.07.20	Second Systematic Review and Meta-Analysis Published Demonstrating DecisionDx-Melanoma as Independent Predictor of Recurrence, Distant Metastasis and Overall Survival in Cutaneous Melanoma (Businesswire)
02.07.20	Castle Biosciences Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares of Common Stock (Businesswire)
25.06.20	Castle Biosciences Announces Pricing of $74.0 Million Public Offering of Common Stock (Businesswire)
22.06.20	Castle Biosciences Announces Proposed Underwritten Public Offering of Common Stock (Businesswire)
22.05.20	Castle Biosciences Announces Change of Location of Annual Meeting of Stockholders to Be Held June 4, 2020 (Businesswire)
19.05.20	New Data Demonstrates Significant and Risk-Appropriate Clinical Impact of DecisionDx-SCC Test Results on Patient Management Decisions (Businesswire)
11.05.20	Castle Biosciences Announces First Quarter 2020 Results (Businesswire)
05.05.20	Castle Biosciences Announces Publication of a Study Evaluating Incorporation of DecisionDx-SCC into Management of High-Risk Cutaneous Squamous Cell Carcinoma (Businesswire)
29.04.20	Castle Biosciences Announces Publication of Validation Study for DecisionDx-SCC, Showing this Test is an Independent Predictor of Metastatic Risk in Squamous Cell Carcinoma (Businesswire)
27.04.20	Castle Biosciences to Release First Quarter 2020 Financial Results and Host Conference Call on Monday, May 11, 2020 (Businesswire)
06.04.20	Castle Biosciences to Present at the 19th Annual Needham Virtual Healthcare Conference (Businesswire)
02.04.20	Castle Biosciences Appoints Miles Harrison to Board of Directors (Businesswire)
01.04.20	Castle Biosciences Announces Publication of a Systematic Review and Meta-Analysis Demonstrating DecisionDx-Melanoma Test as Independent, Significant Predictor of Recurrence and Metastatic Risk (Businesswire)
27.03.20	Castle Biosciences Posts Results of Collaborative Ocular Oncology Group Survey on the Management of Ocular Oncology Patients During the COVID-19 Pandemic (Businesswire)
26.03.20	Castle Biosciences Announces Publication of Fourth Study Demonstrating Significant Impact of DecisionDx-UM on Treatment Plan Recommendations for Patients with Uveal Melanoma (Businesswire)
10.03.20	Castle Biosciences Announces Fourth Quarter and Full-Year 2019 Results (Businesswire)
05.03.20	Castle Biosciences Announces Issuance of First U.S. Patent Covering DecisionDx-Melanoma (Businesswire)
25.02.20	Castle Biosciences to Release Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on Tuesday, March 10, 2020 (Businesswire)
12.02.20	Castle Biosciences to Present at the 9th Annual SVB Leerink Global Healthcare Conference (Businesswire)
20.01.20	Castle Biosciences Announces Study Establishing the Value of Integrating DecisionDx-SCC Test into Management of High-Risk Cutaneous Squamous Cell Carcinoma (Businesswire)
09.01.20	Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2019 Performance Results, Delivering 29% DecisionDx-Melanoma Test Report Volume Growth in 2019 (Businesswire)
30.12.19	Castle Biosciences Announces Level of Evidence Review on DecisionDx-Melanoma Published in Latest Issue of American Journal of Clinical Dermatology (Businesswire)
18.12.19	Castle Biosciences Added to NASDAQ Biotechnology Index (Businesswire)
12.12.19	Healthcare IPOs That Delivered Solid Returns In 2019 (RTTNews)
03.12.19	Castle Biosciences Announces Time Change for Presentation at the Evercore ISI Second Annual HealthCONx (Businesswire)
25.11.19	Castle Biosciences Presents Expanded Data Supporting Use of DecisionDx-Melanoma Test to Inform Sentinel Lymph Node Biopsy Recommendations (Businesswire)
20.11.19	Castle Biosciences to Present at Upcoming Investor Conferences (Businesswire)
13.11.19	Today's Top 5 Gainers In Healthcare Sector (AMRN, DMAC, TNXP...) (RTTNews)
12.11.19	ASLN Slumps As TreeTopp Flops, CSTL On Watch, KDMN Rocks, NXTC Down 53% (RTTNews)
11.11.19	Castle Biosciences Reports Third Quarter 2019 Results (Businesswire)
31.10.19	Study Results Confirm Newly Developed Nomogram Using Castle Biosciences’ DecisionDx-Melanoma Test Improves Assessment of Melanoma Patient Risk (Businesswire)
29.10.19	Castle Biosciences Presents Clinical Validation Study for its Cutaneous Squamous Cell Carcinoma Prognostic Test at the American Society for Dermatologic Surgery (ASDS) 2019 Annual Meeting (Businesswire)
28.10.19	Castle Biosciences to Release Third Quarter 2019 Financial Results and Host Conference Call on Monday, November 11, 2019 (Businesswire)
28.10.19	Castle Biosciences Presents Second Study Confirming Ability of DecisionDx-Melanoma to Inform Sentinel Lymph Node Biopsy Decisions at the 8th International Congress on Cancer Metastasis (Businesswire)
18.10.19	Castle Biosciences Presents Data at the ASDP 56th Annual Meeting Supporting DecisionDx-Melanoma Test’s Ability to Identify T1 Melanoma Patients at Low Risk for a Positive Sentinel Lymph Node (Businesswire)
16.10.19	Castle Biosciences Announces Presentation of Prospective, Multicenter Study Demonstrating Significant Impact of DecisionDx-UM on Treatment Plan Recommendations for Patients with Uveal Melanoma (Businesswire)
07.10.19	Newly Published Systematic Review Confirms Strength of Evidence and Outlines Appropriate Use Criteria for Integration of DecisionDx-Melanoma in Management of Patients with Cutaneous Melanoma (Businesswire)
19.09.19	Castle Biosciences Added to Membership of US Small-Cap Russell 2000® Index (Businesswire)
04.09.19	Castle Biosciences Announces Time Change for Presentation at the Baird 2019 Global Healthcare Conference (Businesswire)
03.09.19	Castle Biosciences Reports Second Quarter 2019 Results (Businesswire)
27.08.19	Castle Biosciences to Present at the Baird 2019 Global Healthcare Conference (Businesswire)
22.08.19	Castle Biosciences to Release Second Quarter 2019 Financial Results and Host Conference Call on Tuesday, September 3, 2019 (Businesswire)
29.07.19	Castle Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares (Businesswire)
25.07.19	Castle Biosciences Announces Pricing of Initial Public Offering (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Castle Biosciences Inc Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten